Humanigen IncOver The Counter Market:HGENQ
- LAST PRICE0.0002
- TODAY'S CHANGE (%)-0.0065 (-97.0149%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0067
- Day Range
- 52 Week Range
- Volume48,522
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HGENQ |
|---|---|---|
| 10:19 ET | 10637 | 0.0001 |
| 10:21 ET | 6310 | 0.0001 |
| 11:13 ET | 6400 | 0.0001 |
| 12:16 ET | 500 | 0.0002 |
| 12:18 ET | 387 | 0.0002 |
| 01:12 ET | 12000 | 0.0002 |
| 01:39 ET | 300 | 0.0002 |
| 02:36 ET | 9999 | 0.0002 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Humanigen Inc | 23.8K | 0.0x | --- |
DNAPrint Genomics Inc | 640.0 | 0.0x | --- |
Infinity Pharmaceuticals Inc | 90.0 | 0.0x | --- |
Adynxx Inc | 10.0 | 0.0x | --- |
Rayont Inc | 25.1K | 0.0x | --- |
Aeolus Pharmaceuticals Inc | 150.0 | 0.0x | --- |
Company Information
Humanigen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing its portfolio of proprietary Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. Its product candidate, lenzilumab, and its other product candidate, ifabotuzumab (iFab), are Humaneered monoclonal antibodies are Humaneered monoclonal antibodies. lenzilumab is used as a therapeutic for chronic myelomonocytic leukemia; for the prevention of acute graft versus host disease; and as a prophylactic companion for certain chimeric antigen receptor therapy (CAR-T) programs. The Company has developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to optimize them.
Contact Information
- Headquarters
- 830 MORRIS TURNPIKE, 4TH FLOORSHORT HILLS, NJ, United States 07078
- Phone
- 973-200-3100
- Fax
- 302-531-3150
Executives
- Chairman of the Board, Chief Executive Officer, Acting Chief Financial Officer
- Cameron Durrant
- Chief Scientific Officer, Director
- Dale Chappell
- Independent Director
- Ronald Barliant
- Independent Director
- Rainer Boehm
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $23.8K |
|---|---|
Revenue (TTM) | $1.7M |
Shares Outstanding | 119.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.17 |
EPS | $-0.66 |
Book Value | $-0.39 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,061.21% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
